No link found between extra temozolomide and living longer
Original title: No association between temozolomide maintenance and survival after first-line treatment in primary CNS lymphoma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looks at people already getting treatment, and it did not show a benefit.
The short version
Staying on the drug temozolomide after first treatment was not linked to living longer.
What was studied. This report looked at people with a cancer that starts in the brain or spinal cord. It looked at the drug temozolomide, taken to keep the cancer away after the first round of treatment.
What they found. The report found no link between staying on temozolomide and how long people lived. Only the title of this report is available. No numbers, no group sizes, and no other details were given.
What this means, and what it doesn't
What it could mean: For now, there is no sign here that staying on this drug helps people live longer. Your own care team knows your case and can tell you what fits you.
What it doesn't mean: This does not mean the drug is bad or that anyone should stop taking it. It also does not mean the question is settled. Only the title of this report is available, so the details cannot be checked. This is a research report, not a change in care, and it is not a promise of a cure.
Source: PubMed, August 17, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.